← Back to Search

Imaging Agent

Near Infrared Imaging for Lung Cancer

Phase 1

Waitlist Available

Led By Yolonda L. Colson, MD, PhD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing if surgeons can find and remove the first lymph node that a tumor drains into. Doing this could help improve the ability to find and remove all tumor cells.

Eligible Conditions

Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To evaluate the safety and efficacy of near-infrared technology to guide therapeutic sentinel lymph node dissection in patients with lung cancer.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Near Infrared ImagingExperimental Treatment1 Intervention

The intervention to be administered is indocyanine green dye.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Near Infrared Imaging

2013

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,079 Previous Clinical Trials

340,891 Total Patients Enrolled

Brigham and Women's HospitalOTHER

1,609 Previous Clinical Trials

11,470,270 Total Patients Enrolled

Beth Israel Deaconess Medical CenterOTHER

836 Previous Clinical Trials

13,010,279 Total Patients Enrolled

Media Library

Near Infrared Imaging (Imaging Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00264602 — Phase 1

Lung Cancer Research Study Groups: Near Infrared Imaging

Lung Cancer Clinical Trial 2023: Near Infrared Imaging Highlights & Side Effects. Trial Name: NCT00264602 — Phase 1

Near Infrared Imaging (Imaging Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00264602 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum capacity for enrolment in this medical experiment?

"This research initiative is no longer searching for applicants. It was first posted on February 18th 2009 and last updated April 22nd 2022. Currently, there are 1628 trials recruiting patients with lung cancer and 30 studies that require participants to undergo Near Infrared Imaging."

Answered by AI

Could you elaborate on the potential risks associated with Near Infrared Imaging procedures?

"Due to limited evidence of Near Infrared Imaging's efficacy and safety, we have estimated the technology's hazard rating at a 1."

Answered by AI

Is recruitment for this trial still available?

"This clinical trial, first posted on February 18th 2009 and last updated April 22nd 2022, is not currently enrolling participants. Nonetheless, there are 1,658 other medical studies actively seeking candidates at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

Yolonda Colson, MD, PhD 2009. "Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00264602.

All > Lung